Adding socioeconomic background to EEG brain recordings slightly improved how well a deep-learning model sorted 127 US university students by ADHD screening status. Accuracy rose on all 4 brain-recording tasks, but the gain was not statistically significant on any of them.1 Research Highlights About 9 in 10 classified correctly from EEG alone: tested on students …
Teens who have both ADHD and developmental coordination disorder (DCD) reported less resilience, less hope and a weaker sense that life is manageable and meaningful than typical teens, according to a 2026 study of 105 Israeli adolescents.1 Research Highlights Lower scores with both conditions: the 23 teens with ADHD plus DCD scored lower than 45 …
About 9 in 10 children referred for ADHD or autism had elevated symptoms in at least 2 of 4 areas — ADHD, autism, defiance and learning problems — and the same overlap showed up in ordinary community children at lower rates, according to a 2026 Pennsylvania study based on mothers’ ratings.1 Research Highlights Overlap was …
Adults with type 2 diabetes who also had ADHD died at a higher rate than those without ADHD in a 2026 study of 1.9 million adults newly diagnosed with diabetes across 7 countries. They did not, however, have more heart attacks, strokes or cardiovascular deaths.1 Research Highlights Higher death rate with ADHD: after adjusting for …
Among broad child behavior questionnaires used to screen for ADHD, the short hyperactivity-inattention subscale of the Strengths and Difficulties Questionnaire (SDQ) has the strongest measurement evidence, according to a 2026 review of 36 studies. None of the 12 scales reviewed met every quality standard.1 Research Highlights 36 studies, 12 scales: a systematic review in BMC …
A 2026 meta-analysis of 50 studies estimated that about 1 in 3 people with neurofibromatosis type 1 (NF1) have ADHD (33%), and that roughly 1 in 10 have autism (11%), seizures (11%), depression (13%), or anxiety (12%).1 Every one of those figures sits well above typical population rates, but the individual studies disagreed so widely …
A 2026 medRxiv preprint using parent-cocreated sensory-related outcome measures found that 83% of children and teens improved on at least 1 PROMIS domain during 6 months of bumetanide treatment.1 The result is interesting, but the unmasked single-case design means the strongest claim is about sensitive outcome tracking, not definitive bumetanide efficacy. Research Highlights Most participants …